Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients.
about
New directions for pharmacotherapy in the treatment of acute coronary syndrome.Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients.Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study.Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?Intra-coronary morphine versus placebo in the treatment of acute ST-segment elevation myocardial infarction: the MIAMI randomized controlled trial
P2860
Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Abciximab as a bridging strate ...... interaction in STEMI patients.
@en
Abciximab as a bridging strate ...... interaction in STEMI patients.
@nl
type
label
Abciximab as a bridging strate ...... interaction in STEMI patients.
@en
Abciximab as a bridging strate ...... interaction in STEMI patients.
@nl
prefLabel
Abciximab as a bridging strate ...... interaction in STEMI patients.
@en
Abciximab as a bridging strate ...... interaction in STEMI patients.
@nl
P2093
P2860
P356
P1476
Abciximab as a bridging strate ...... interaction in STEMI patients.
@en
P2093
Bernd Jilma
Dimitrios Alexopoulos
Eva-Luise Hobl
Günter Christ
Irene M Lang
Raffaele De Caterina
Simon Specht
P2860
P304
P356
10.1111/BCP.13053
P407
P577
2016-07-01T00:00:00Z